12:00 AM
Mar 26, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Protelos strontium ranelate regulatory update

EMA's CHMP concluded the benefits of Servier's Osseor/Protelos strontium ranelate continue to outweigh the risk, but recommended the drug's label be contraindicated in patients with venous thromboembolism or who are temporarily or permanently immobilized. CHMP...

Read the full 155 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >